Primary Vitreoretinal Lymphoma
Oncology
Prevalence
56.0 / 100K
Incidence
19.6 / 100K/yr
1 drug in development·1 company·0 clinical trials
Drug Pipeline by Phase
Phase 2(1)
| Drug | Company |
|---|---|
| ADX-2191 | Aldeyra Therapeutics, Inc. (ALDX) |
Frequently asked questions
How many drugs are in development for Primary Vitreoretinal Lymphoma?
BioSniper tracks 1 drug in development for Primary Vitreoretinal Lymphoma across 1 company.
What is the prevalence of Primary Vitreoretinal Lymphoma?
The estimated prevalence of Primary Vitreoretinal Lymphoma is approximately 56.0 per 100,000 population.
Deep-dive into Primary Vitreoretinal Lymphoma
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis